LPL and hyperlipidemia: This is in agreement with the known role of PCSK6 in lipid metabolism, where it cleaves and inactivates endothelial lipase (EL) and lipoprotein lipase (LPL) (Jin et al., 2005), which can lead to hyperlipidemia (Choi and Korstanje, 2013).